There was a new teaser email from the Oxford Income Letter folks this morning that caught my eye… and in these tumultuous days, when I don’t really feel like doing any trading around these short-term gyrations caused by pandemic panic and political pandering, I confess to being extra-interested in relatively stable dividend-paying investments. So let’s […]
My favorite kind of ads are the ones that throw in some archeology and a secret historical treasure… I guess I’m just a dime-store novel kind of guy at heart. And this week we’ve got just that from Marc Lichtenfeld, who’s peddling his Oxford Income Letter ($49, renews at $79/yr) with headlines about a secret […]
Turn down the football game and bring out the pies, it’s that time again! Stock Gumshoe is mostly closed down for the holiday week, but we do have to continue our annual tradition of calling out our “Turkey of the Year” … so take a pause from arguing with your family and join us, won’t […]
The latest pitch from Marc Lichtenfeld begins with a walking tour of Palm Beach, which is just cruel to those of us enduring mud season in New England, but, more importantly, it also comes with a good ol’ fake deadline of midnight tonight… so I guess I better cover this one quick! Fortunes await! The […]
Higher-cost trading service that appears to speculate on “ignition events” using options, mostly betting on companies that are predicted to initiate a dividend in the near future.
This teaser solution was originally published in a Friday File for the Irregulars on November 30. The same ad is still circulating and several new folks have asked about it, so I’m releasing it for all to read today. What follows has not been updated since the end of November, and the ad is also […]
I don’t have any big updates on the Real Money Portfolio this week, or on my big-picture thinking (still holding a lot more cash than usual, still being mindful of stop loss triggers for momentum/growth stocks, still hoping some of my favorites will reach prices that inspire a buy soon, since we’re right in the […]
Have you been watching what’s going on with the trendy pot stocks lately? Holy crap. This reminds me now of 1999 more than it reminds me of the cryptocurrency bubble of this past winter — these larger marijuana companies, like many of the dot com companies (and unlike most cryptos, of course), are real businesses […]
The beginning of the latest ad from Marc Lichtenfeld’s Lightning Trend Trader is good and juicy, at the very least… how could you not open up the ad and pay attention? “The KILLER Hiding in Your Medicine Cabinet “These Common Drugs Take a Life Every 12 Minutes (Who’s at Risk?) “Here’s the NEW Breakthrough and […]
Fear Of Missing Out is such a big deal that it gets its own acronym in my book (FOMO — and a clever FOMO-fueling website here), and it drives investors to take huge chances just so they don’t have to worry about missing a chance at stupendous gains. That’s what many newsletter ads use to […]
Welcome back from vacation, me! There’s no question what ad should be covered first as I brush the sand off my feet and turn up the heat here at Gumshoe HQ… it’s the pitch from Marc Lichtenfeld for his Lightning Trend Trader over at Oxford Club, and the “special report” he’s dangling as bait. That […]
This stock certainly has Gumshoe Nation in a bit of a lather… though it’s also one that many of you already know about, and the solution to this teaser is not super-secret (it has been posted in recent discussions here at Stock Gumshoe a few times). Marc Lichtenfeld puts out a newsletter advisory called Lightning […]
This article originally appeared on July 22, 2015, and the bulk of it has not been updated or revised since. The meat of the ad is essentially the same, and if Lichtenfeld really “bet his paycheck” on this stock (which was and is Alnylam) on July 22 he’s so far lost about 65% of that […]
Nobody likes a monopoly… except investors, of course. We love monopolies, as long as we can own shares. There’s almost nothing better than a lack of competition, because that gives pricing power and better margins and a nice steady stream of profits. And if you can own a monopoly company that also pays out a […]
Marc Lichtenfeld has an ad running this week that talks about a business that could be the “most profitable I’ve ever seen” — and one that’s so entrenched in our country that he says the equivalent of 10% of US GDP relies on this one company. So who is it? Well, he gets into some […]
Marc Lichtenfeld’s trading service that tries to “ride the lightning” by uncovering catalysts that will send stocks soaring. Often covers biotech stocks.
This article originally ran on January 12… the teaser pitch was still being circulated heavily last week, and the stock released earnings on February 3 that disappointed investors, bringing shares down about 15% (it was teased as a “$7 biotech,” and briefly $8, before then). The original Jan. 14 “special event” catalyst teased by Lichtenfeld, […]
[This article was originally published on May 29, 2014, we’re bumping it back to the top because a lot of readers have asked about it this week. The article below has not been updated or revised since first publication on 5/29/14] Gumshoe readers have been asking about the “President’s Private Stock Market” for quite a […]
Another Monday morning, another “next wave of the internet” teaser. This teaser comes in from the Oxford Income Letter, edited by Marc Lichtenfeld over at the Oxford Club, and it’s a bit of a departure from the crazy small cap names he has more often touted of late (usually for his MicroCap Tech Trader newsletter). […]
Publishes educational material for investors.
I’ve got a handful of updates for you, including one on a stock that I bought yesterday and a few other notes about recent quarterly reports from stocks I follow, but first … a teaser to solve … When I wrote about Marc Lichtenfeld’s pitch for “Spread Trusts” yesterday, I promised to also try to […]
Monthly newsletter focusing on income investments.
Every biotech-related teaser ad promises that you can make life-changing profits while also curing the world of a dread disease, of course — that’s why we love ’em. But this one’s a little bit different — they are teasing a biotech company that is trying to develop new drugs, but according to the pitch this […]
Marc Lichtenfeld, who we’ve covered a number of times in this space, focuses largely on biotech investments — he’s teased a number of them for a variety of different newsletters that he has helmed or contributed to, but it looks like he’s now launching a new letter from the Oxford Club called FirstLine Investor Alert. […]
Biotech-focused newsletter from Lichtenfeld, who previously edited the similar-sounding Access Group letters for White Cap Research.
Last year Marc Lichtenfeld started promoting a new service in which he promised to identify “active shares” that effectively let you choose your own price — and although he had plenty of hype in that letter that sounded utterly foolish, as usual, he was at least partly right about the stock’s performance (he got the […]
Weekly newsletter with recommendations of stocks that are or may be targeted by activist investors. No longer publishing.
Today’s delightful tidbit of teasermania comes in from Marc Lichtenfeld, who tends to focus on biotech and health care stocks. He’s been around for a while, and is now drumming up members for the Oxford Club instead of one of his own biotech-focused letters, and pitching some ideas that sound like they’re a little larger […]
That headline came across my desk on a tease from Marc Lichtenfeld, who I’ve certainly covered in the past — but this time, he’s teasing a brand new advisory called The Activist Trader that apparently hasn’t even started publishing yet. So in case you’re tempted to become one of his guinea pigs, let’s look and […]
Ah, a good old promise of biotech riches — I haven’t dug into one of these in ages, nothing beats the wild biotech stocks that can see their share price climb 200% (or fall 90%) on a single bit of news. This tease is from Marc Lichtenfeld, whose biotech stuff we’ve looked at several times […]
Now this is a nice promise: “If This Stock Doesn’t Double Between Now and June 25, I’ll Write You an Apology – Along With a Check for $1,250” Of course, one assumes that this only applies to the folks who pony up that same $1,250 for a subscription to the Access Research Group newsletter (and, […]
That sounds pretty good, right? It’s everyone’s dream, a rich great-uncle that you never knew, and years later you find out that you were left a fortune in his will, and he’s been dead for years and a banker’s knocking at the door trying to give you a bag full of Krugerrands. Ah, those are […]
This ad has been crashing in on Gumshoe beach in massive waves over the last week, so I thought it might be time to take a gander. It’s for the Xcelerated Profits report at Mt. Vernon Research — the last time I saw a similar ad it was from Karim Rahemtulla for this same report, […]
This is an ad that probably many of you have already seen, from Marc Lichtenfeld for his Access Group newsletter. And yes, like so many ads do, they’re guaranteeing that you’ll double your money if you invest in this idea. Which gives me a chance for a quick little digression before we dig into the […]
Healthcare-focused newsletter, recommended stocks primarily of emerging device and biotech companies. Was helmed by Marc Lichtenfeld, who moved on to other publications, but stopped publishing after a short while — Lightning Trend Trader, a current publication of Lichtenfeld’s with The Oxford Club, sometimes covers biotech stocks.
Today’s teaser ad is from Marc Lichtenfeld and his Access Group — they specialize in part on medical and biotech stocks, and the first two ads we’ve looked at them are in that area. The first one was for the “$4 Cancer Detection Device that could go to $196,” which you might remember turned out […]
This one comes in from what looks to be a new newsletter service called “The Access Group” that will run you $2,750 a year. Phew. This is a service that they claim will enable individual investors to get access to the kind of research hedge fund companies used to pay these analysts $30,000 a year […]